← All Sponsors
SPONSOR

Flare Therapeutics Inc.

Total Trials
1
Recruiting
1
Phases
Phase 1
Conditions studied: Advanced Urothelial CarcinomaOral Drug AdministrationOpen Label
NCT05929235 Phase 1
Recruiting

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Advanced Urothelial Carcinoma
United States View Trial →